NON-MEDICAL SWITCH BETWEEN ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS - A MULTICENTRE STUDY ON EFFICACY AND DRUG SUSTAINABILITY

被引：0
|
作者：
Lontai, Livia
Gonczi, Lorant
Balogh, Fruzsina
Komlodi, Nora
Resal, Tamas
Farkas, Klaudia
Molnar, Tamas
Miheller, Pal
Golovics, Petra A.
Schafer, Eszter
Szamosi, Tamas
Ilias, Akos
Lakatos, Peter L.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1507
引用
收藏
页码：S606 / S606
页数：1
相关论文
共 50 条
  • [41] SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY
    Mazza, S.
    Sed, Piazza O. N.
    Conforti, F. S.
    Fasci, A.
    Casini, V
    Ricci, C.
    Munari, F.
    Pirola, L.
    Invernizzi, P.
    Girelli, C.
    Lupinacci, G.
    Pastorelli, L.
    Cavallaro, F.
    Ferraris, L.
    Colucci, A.
    Amato, A.
    Tontini, G. E.
    Vecchi, M.
    Fiorino, G.
    Caprioli, F.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S159 - S159
  • [42] Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2022, 85 (04) : 557 - 564
  • [43] Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting
    De Somer, T.
    Deprez, N.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanden Branden, S.
    Vanderstraeten, E.
    Vandervoort, J.
    Van Heddegem, N.
    Dewint, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S406 - S406
  • [44] Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease
    Haghnejad, Vincent
    Le Berre, Catherine
    Dominique, Yoann
    Zallot, Camille
    Guillemin, Francis
    Peyrin-Biroulet, Laurent
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 281 - 288
  • [45] Efficacy of Adalimumab in Patients With Crohn's Disease and Symptomatic Small Bowel Stricture: A Multicentre, Prospective, Observational Cohort Study (CREOLE)
    Bouhnik, Yoram
    Carbonnel, Franck
    Laharie, David
    Stefanescu, Carmen
    Hebuterne, Xavier
    Abitbol, Vered
    Nachury, Maria
    Brixi, Hedia
    Bourreille, Arnaud
    Picon, Laurence
    Bourrier, Anne
    Allez, Matthieu
    Peyrin-Biroulet, Laurent
    Moreau, Jacques
    Savoye, Guillaume
    Fumery, Mathurin
    Nancey, Stephane
    Roblin, Xavier
    Altwegg, Romain
    Bouguen, Guillaume
    Bommelaer, Gilles
    Danese, Silvio
    Louis, Edouard
    Mary, Jean-Yves
    GASTROENTEROLOGY, 2015, 148 (04) : S62 - S62
  • [46] Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort study (CREOLE)
    Bouhnik, Y.
    Carbonnel, F.
    Laharie, D.
    Stefanescu, C.
    Hebuterne, X.
    Abitbol, V.
    Nachury, M.
    Brixi, H.
    Bourreille, A.
    Picon, L.
    Bourrier, A.
    Allez, M.
    Peyrin-Biroullet, L.
    Moreau, J.
    Savoye, G.
    Fumery, M.
    Nancey, S.
    Roblin, X.
    Altwegg, R.
    Bouguen, G.
    Bommelaer, G.
    Danese, S.
    Louis, E.
    Mary, J. -Y.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S41 - S41
  • [47] Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study
    Bouhnik, Yoram
    Carbonnel, Franck
    Laharie, David
    Stefanescu, Carmen
    Hebuterne, Xavier
    Abitbol, Vered
    Nachury, Maria
    Brixi, Hedia
    Bourreille, Arnaud
    Picon, Laurence
    Bourrier, Anne
    Allez, Matthieu
    Peyrin-Biroulet, Laurent
    Moreau, Jacques
    Savoye, Guillaume
    Fumery, Mathurin
    Nancey, Stephane
    Roblin, Xavier
    Altwegg, Romain
    Bouguen, Guillaume
    Bommelaer, Gilles
    Danese, Silvio
    Louis, Edouard
    Zappa, Magaly
    Mary, Jean-Yves
    GUT, 2018, 67 (01) : 53 - +
  • [48] Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
    Chang, Chen-Wang
    Wei, Shu-Chen
    Chou, Jen-Wei
    Hsu, Tzu-Chi
    Chuang, Chiao-Hsiung
    Lin, Ching-Pin
    Hsu, Wen-Hung
    Yen, Hsu-Heng
    Lin, Jen-Kou
    Fang, Yi-Jen
    Wang, Horng-Yuan
    Lin, Hung-Hsin
    Wu, Deng Cheng
    Ni, Yen Hsuan
    Wang, Cheng-Yi
    Wong, Jau-Min
    INTESTINAL RESEARCH, 2014, 12 (04) : 287 - 292
  • [49] A single-centre, observational, retrospective, real-life study evaluating adalimumab biosimilar ABP 501 in the treatment of plaque-type psoriasis and psoriatic arthritis in originator-naive patients and in patients undergoing non-medical switch from originator
    Giunta, A.
    Zangrilli, A.
    Bavetta, M.
    Manfreda, V.
    Pensa, C.
    Bianchi, L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1099 - 1102
  • [50] Evaluating the nocebo effect in a non-medical switching program from originator to biosimilar infliximab in patients with inflammatory bowel disease: A real yet temporary phenomenon
    Dutt, K.
    Srinivasan, A.
    Van Langenberg, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 116 - 117
12345